

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In application of: **Finer et al.**

Application No.: 09/724,941

Filed: November 28, 2000

Title: **METHODS AND COMPOSITIONS
UTILIZING QUINAZOLINONES**

Attorney Docket No.: CYTOP009C6

Examiner: UNASSIGNED

Group: 1614

103
RECEIVED

SEP 12 2002

TECH CENTER 1600/2900

COPY OF PAPERS
ORIGINALLY FILED

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail to Commissioner for Patents, Washington, DC 20231 on September 4, 2002.

Signed: _____

Sandra Halliwell

**INFORMATION DISCLOSURE STATEMENT
37 CFR §§ 1.56 AND 1.97(b)**

Commissioner for Patents
Washington, DC 20231

Dear Sir:

The references listed in the attached PTO Form 1449 may be material to the examination of the above-identified patent application. Applicants submit the list of these references in compliance with their duty of disclosure pursuant to 37 CFR §§ 1.56 and 1.97. The Examiner is requested to make these references of official record in this application. The above-identified application is a continuation of prior application U.S. Patent Application No. 09/699,047, which is being relied upon for an earlier filing date under 35 U.S.C. § 120. Because the listed references were either cited by the PTO, or submitted to the PTO in the prior application, under 37 CFR § 1.98(d) Applicants submit that copies need not be provided.


This Information Disclosure Statement is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that these references indeed constitute prior art.

This Information Disclosure Statement is being filed after the mailing date of the first Office Action on the merits, or after three months of the filing date of this application, whichever event occurred last, but it is believed before the mailing date of either: (i) a final action under § 1.113 or (ii) a notice of allowance under § 1.311, whichever occurs first.

The Commissioner is hereby authorized to charge the appropriate fees to process this document to Deposit Account 501339.

Respectfully submitted,

BEYER WEAVER & THOMAS, LLP

A handwritten signature in black ink, appearing to read "Lauren L. Stevens", with a stylized flourish at the end.

Lauren L. Stevens

Registration No. 36,691

P.O. Box 778
Berkeley, CA 94704-0778

Information Disclosure
Statement By Applicant

Applicant:

Finer et al.

Filing Date

11/28/00

Group

1614

(Use Several Sheets if Necessary)

U.S. Patent Documents

Examiner Initial	No.	Patent No.	Date	Patentee	Class	Sub-class	Filing Date
	1	3,322,756	05/30/1967	Ruschig et al.			
	2	3,723,432	03/27/1973	Ott			
	3	3,740,442	06/19/1973	Ott et al.			
	4	3,925,548	12/09/1975	Oh			
	5	4,981,856	01/01/1991	Hughes			
	6	5,147,875	09/15/1992	Coates et al.			
	7	5,187,167	02/16/1993	Hughes			
	8	5,204,354	04/20/1993	Chakravarty et al.			
	9	5,280,027	01/18/1994	Andrew et al.			
	10	5,747,498	05/05/1998	Schnur et al.			
	11	5,773,476	06/30/1998	Chen et al.			
	12	5,922,866	07/13/1999	Miyata et al.			

Foreign Patent or Published Foreign Patent Application

Examiner Initial	No.	Document No.	Publication Date	Country or Patent Office	Class	Sub-class	Translation	
							Yes	No
	13	EP 360417 A2/A3	28.03.1990	EPO			X	
	14	EP 884316 A1	16.12.1998	EPO			X	
	15	EP 884319 A2/A3	16.12.1998	EPO			X	
	16	WO 94/21259	29.09.1994	WIPO/PCT			X	
	17	WO 96/19224	27.06.1996	WIPO/PCT			X	
	18	WO 97/43276	20.11.1997	WIPO/PCT			X	
	19	WO 98/34613	13.08.1998	WIPO/PCT			X	
	20	WO 01/23364	05.04.2001	WIPO/PCT			X	
	21	WO 01/23365	05.04.2001	WIPO/PCT			X	
	22	WO 01/25235	12/04.2001	WIPO/PCT			X	
	23	WO 01/42216	14.06.2001	WIPO/PCT			X	
	24	WO 01/52234	19/07/2001	WIPO/PCT			X	
	25	WO 01/66519	13.09.2001	WIPO/PCT				X

Other Documents

Examiner Initial	No.	Author, Title, Date, Place (e.g. Journal) of Publication
	26	Ager et al., "Synthesis and Central Nervous System Activity of Quinazolones Related to 2-Methyl-3-(o-tolyl)-4(3H)-quinazolone (Methaqualone)", Jnl of Med. Chem., (1977) Vol. 20, No. 3, pp. 379-86
	27	AU-A-12617/88, Australian patent application "New N-substd. Omega-aminoacid derives. - which are selective inhibitors of human plasma renin" (1988)
	28	Tiwari et al., "Synthesis and CNS Activity of 2-Aryl-3(3', 4'-Dihydroxyphenylethyl) 6-8-substituted-4 (3H)-Quinazolinones", Indian Jnl of Pharm. Sciences, Mar/Apr 1978, pp. 40-43
	29	Rao et al., "Synthesis and Biological Activities of Certain Derivatives of 3-Aryl-4(3H)-quinazolinones. Part-II", J. Indian Chem. Soc., Vol. LXII, Mar 1985, pp.234-37
Examiner		Date Considered

Examiner: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Duplicate of Paper #12

